Ipilimumab is an anti-CTLA-4 inhibitor that expands the range of available tumor immunotherapy approaches, in contrast to the widespread use of single-drug PD-1/PD-L1 inhibitors in the field of tumor therapy. The gene discussed is CTLA4; the disease is neoplasm.